MorphoSys AG
MOR.DEDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
MOR03087 phase 1 dose escalation
Multiple Myeloma
Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell
Tafasitamab
Diffuse Large B-cell Lymphoma
MOR00208 (formerly Xmab 5574)
Non-Hodgkin Lymphoma
MOR103
Rheumatoid Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MOR03087 phase 1 dose escalation | Phase 2 | Multiple Myeloma | - | - |
Idelalisib | Phase 2 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
Tafasitamab | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
MOR00208 (formerly Xmab 5574) | Phase 2 | Non-Hodgkin Lymphoma | - | - |
MOR103 | Phase 2 | Rheumatoid Arthritis | - | - |
Frequently asked questions
What is in MorphoSys AG's drug pipeline?→
CatalystAlert tracks 5 drug candidates in MorphoSys AG's (MOR.DE) pipeline across Phase 2. Its lead program is MOR03087 phase 1 dose escalation (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MorphoSys AG's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for MorphoSys AG (MOR.DE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MOR.DE biotech catalysts?→
Add MOR.DE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MorphoSys AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.